CONFERENCE DAY ONE

Wednesday, May 28, 2025

7:30 am Check In & Morning Coffee

8:30 am Chair’s Opening Remarks

REVOLUTIONIZING OPHTHALMOLOGY THROUGH ARTIFICIAL INTELLIGENCE TO DETECT EARLIER VISION LOSS

9:00 am Panel Discussion: Delving into the Ethical, Economic & Legal Barriers to AI Algorithm Application in Ophthalmic Trials

  • Mohammad Eslami Instructor, Harvard Medical School
  • Mayssa Attar Senior Vice President & Head of Pharmaceutical, Consumer Research & Development, Bausch + Lomb
  • Touseef Qureshi Assistant Professor, Cedars-Sinai Medical Center

Synopsis

  • Addressing the complexity of sourcing and processing images from multiple providers while maintaining data integrity and compliance
  • Navigating patient privacy and data security
  • Exploring strategies to demonstrate the clinical validity of AI algorithms and secure Phase 3 trials and market approval

9:30 am Unearthing AI’s Impact on Clinical Retinal Studies to Elevate Outcomes From Recruitment to Results

Synopsis

  • Detailing the protocol design of AI-derived photoreceptor layer abnormalities as an inclusion criterion
  • Exploring AI-derived photoreceptor layer abnormalities as an endpoint
  • Utilizing microperimetry to establish ovel functional endpoints

10:00 am Unmasking Bias and Embracing Uncertainty with AI to Accelerate Ophthalmology

Synopsis

  • Discussing how biases impact diagnostic accuracy, particularly for underrepresented groups
  • Presenting current or emerging methods to identify and reduce bias, such as reweighting datasets or algorithmic fairness interventions
  • Proposing new ways to standardize datasets, external validations, or uncertainty metrics specific to ophthalmic AI

10:30 am Speed Networking

Synopsis

A prime chance to make the most of in-person networking with a niche community of ophthalmic professionals. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.

11:00 am Morning Coffee Break

11:30 am Predicting Pancreatic Cancer Using AI Analysis of Fundus Images of the Retina of Diabetic Patients to Allow for Earlier Detection

Synopsis

  • Exploring the potential presence of early signs of pancreatic cancer in the retina
  • Using AI to analyze retinal vessels and identify distinct features in diabetic individuals who may later develop pancreatic cancer
  • Developing an AI-based prediction model to forecast pancreatic cancer in diabetic patients by analyzing both retinal and pancreatic data which will eventually help detect cancer at early stages

INVESTIGATING THE LATEST ADVANCEMENTS WITH IMAGING BIOMARKERS TO SPEARHEAD DEVELOPMENT

12:00 pm Roundtable: Exploring the State of Play with Biomarkers for AMD, GA & IRD

Synopsis

Join conversations with your fellow peers to discuss developments with structural and function biomarkers

for specific ophthalmic diseases

Moderator Feedback & Audience Debate

  • Moderators will be assigned to each roundtable to facilitate discussion and collate the findings
  • Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate

AMD | GA | IRD

12:30 pm Session Reserved for iCare

1:00 pm Networking Lunch

2:00 pm Discussing the Technologies & Biomarkers Addressing Specific Disease States, with a Focus on Structural & Functional Biomarkers

  • Francesca Cordeiro Professor of Glaucoma and Retinal Neurodegeneration Studies, University College London - UCL

Synopsis

  • Summarizing the status of existing structural and functional endpoints in AMD
  • Predicting GA growth and direction of growth
  • Highlighting non-responders to therapy early in AMD treatment pathways

2:30 pm Utilizing Delayed Near InfraRed Analysis To Identify Novel Features of Non-Exudative AMD in a Natural History Study

Synopsis

  • Interpreting cross-sectional and longitudinal multimodal images suggests that DNIRA provides a “functional footprint” of AMD
  • Addressing the “roadmap” from imaging to biomarker development
  • Considering the opportunities and challenges of integrating prospectively acquired, small datasets into AI-based biomarker development

3:00 pm Afternoon Break & Poster Session

Synopsis

Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversions and relationship building. Explore a range of exciting poster presentations on the latest ophthalmic imaging biomarkers developments and utilize this opportunity to showcase your own innovations. To submit a poster for this session, please contact info@hansonwade.com.

PRECLINICAL DEVELOPMENTS TO ELEVATE TRANSLATIONAL CAPABILITIES TO PREVENT BLINDING DISEASES

3:30 pm Roundtable Discussion: Synergizing Molecular Imaging & Cross-Species Data to Achieve Alignment

Synopsis

A more practical and highly interactive breakout roundtable session where attendees can crowd-source solutions and share opinions on pre-assigned topic areas:

  • Advanced molecular imaging techniques to enhance understanding in smaller models
  • Standardizing data collection methods that align with clinical endpoints
  • Discussing the potential of automating analysis techniques to draw parallels between models

Moderator feedback & audience debate

  • Moderators will be assigned to each roundtable to facilitate discussion and collate the findings
  • Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate

4:00 pm Delving Into How Photopic Visual Function is Preserved in Retinal Remodeling

Synopsis

  • Utilizing a multi-dimensional map of pathophysiology for the P23H mouse model to identifying novel stages of dysfunction and physiological biomarkers
  • Overcoming dramatic and progressive photoreceptor loss with age, to achieve photopic measures of visual acuity and contrast sensitivity remained largely intact up to postnatal day (PND) 300
  • Detailing how hyperactive neuronal activity emerges before aberrant glial and vascular changes, and before the dramatic decline of photopic spatial visual function

4:30 pm End of Conference Day One & Chair’s Closing Remarks

  • Mayssa Attar Senior Vice President & Head of Pharmaceutical, Consumer Research & Development, Bausch + Lomb